#Clinical Trials

NA-931 Cuts Weight Without Major Muscle Loss in Mid-Stage Trial

NA-931 Cuts Weight Without Major Muscle Loss in Mid-Stage Trial

An experimental oral medicine called NA-931 led to substantial weight loss with only modest reductions in lean mass in a randomized phase II trial. Researchers from developer Biomed Industries presented the topline results at the ObesityWeek annual meeting. The highest doses reduced body weight by 13.8% and 11.3% at week 13, compared with 1.9% on placebo. Lean mass fell by 1.7% over the same period, and nausea rates were only slightly higher than placebo. The company says it is advancing NA-931 into phase III testing. The findings are early and come from a small study of 125 adults.

Wegovy Cuts BMI in Children With Obesity as Young as 6, Trial Finds

Wegovy Cuts BMI in Children With Obesity as Young as 6, Trial Finds

Wegovy (semaglutide) significantly reduced body mass index in children ages 6 to 11 with obesity, according to results from the phase III STEP Young trial. Presented at the ObesityWeek annual meeting and published in the New England Journal of Medicine, the study found that treated children lost weight while placebo patients gained it. Researchers also reported slower height gain and frequent gastrointestinal side effects. Drugmaker Novo Nordisk has not said whether it will submit the data to the FDA.